Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed/ Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia

This phase 1 study will evaluate the safety and efficacy of a CAR-T cell therapy directed against two B cell antigens (CD19 CD20) and produced under good manufacturing practice (GMP) conditions using the closed system CliniMACS Prodigy device in B ALL.

开始日期2020-10-16

申办/合作机构

Medical College of Wisconsin

NCT04186520

/ Recruiting临床1/2期IIT

Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.

开始日期2020-05-18

申办/合作机构

Medical College of Wisconsin

NCT03019055

/ Completed临床1期IIT

Phase 1/1b Study of Redirected Autologous T Cells Engineered to Contain an Anti CD19 and Anti CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory CD19 or CD20 Positive B Cell Malignancies

This is a phase 1/1b, interventional single arm, open label, treatment study designed to evaluate the safety and feasibility of infusion of autologous T cells engineered to contain an anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) single chain variable fragment (scFv) coupled to cluster of differentiation CD3ζ (CD3ζ) and co-stimulatory domain 4-1BB (4-1BB) signaling domains in patients with relapsed and/or refractory CD19 or CD20 positive B cell malignancies

开始日期2017-10-16

申办/合作机构

Medical College of Wisconsin

100 项与 Anti-CD19 and anti-CD20 CAR-T cell therapy(The Medical College of Wisconsin, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD19 and anti-CD20 CAR-T cell therapy(The Medical College of Wisconsin, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD19 and anti-CD20 CAR-T cell therapy(The Medical College of Wisconsin, Inc.) 相关的专利（医药）

登录后查看更多信息

100 项与 Anti-CD19 and anti-CD20 CAR-T cell therapy(The Medical College of Wisconsin, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性儿童急性淋巴细胞白血病	临床2期	美国	Medical College of Wisconsin	2020-10-16
难治性 T 急性淋巴细胞白血病	临床2期	美国	Medical College of Wisconsin	2020-10-16
B细胞恶性肿瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
慢性淋巴细胞白血病	临床2期	美国	Medical College of Wisconsin	2020-05-18
滤泡性淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
套细胞淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
边缘区B细胞淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
纵隔大b细胞淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
原发性中枢神经系统淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
小淋巴细胞淋巴瘤	临床前	美国	Medical College of Wisconsin	2017-10-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04186520 (ASH 12022 \| ASH 22022) 人工标引	临床1/2期	B细胞淋巴瘤	21	CAR-20/19-T cells (flexible 8/12 MF arm)	(淵膚簾繭顧顧繭鹹廠壓) = 繭糧願製糧淵積餘齋遞簾構窪製構窪觸願餘構 (鏇範廠廠廠製築憲繭築 ) 更多	积极	2022-11-15
				CAR-20/19-T cells (12-day fixed MF arm)	(淵膚簾繭顧顧繭鹹廠壓) = 網製夢鹽願製觸製艱夢簾構窪製構窪觸願餘構 (鏇範廠廠廠製築憲繭築 ) 更多
NCT03019055 (O158, CTgov)	临床1期	慢性淋巴细胞白血病 \| B细胞淋巴瘤 \| 小淋巴细胞淋巴瘤 \| B细胞恶性肿瘤	26	CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) (CAR-20/19-T Cells (1.0 x10^5 CAR-20/19-T Cells/kg))	簾廠繭蓋艱醖獵衊憲製(衊窪鬱鏇獵簾簾襯蓋鏇) = 鬱鹽衊醖糧襯獵蓋鹹鑰蓋簾襯積遞構淵鏇願襯 (鏇壓鬱壓網鏇簾觸觸醖, 鹽繭繭醖鬱鑰醖醖積簾 ~ 夢願淵築鬱蓋鏇網積鹽) 更多	-	2021-05-07
				CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) (CAR-20/19-T Cells (2.5 x10^5 CAR-20/19-T Cells/kg))	繭艱鹹願衊夢繭憲願蓋(鏇鏇鹹廠遞醖糧夢餘壓) = 鑰顧廠憲窪膚積淵艱鏇鏇糧壓築鬱繭製遞鏇廠 (築鏇遞網憲願製構壓鏇, 餘鹽鏇齋觸願膚膚選鹹 ~ 窪範願鑰鑰網選糧築齋) 更多